Skip to content

immuno-profiling in cervical cancer

Cervical cancer tumor micro-environment immune-profiling and effect on early response to standard chemoradiotherapy in Indian patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/10/037690
Enrollment
60
Registered
2021-10-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

None listed

Sponsors

AIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. FIGO 2008 stage IB2, IIB, IIIB disease. 2. Age 18 years or older and 3. ECOG performance status 0 - 2 4. Histological diagnosis of squamous cell carcinoma, adenocarcinoma or adeno-squamous cell carcinoma of the cervix 5. HB > 9 g/dL; ANC > 1000 / mm3; Plt > 1,00,000/ mm3 6. Bilirubin AST or ALT 7. Adequate renal function: creatinine = 60ml/min or >= 50 ml/min by EDTA creatinine clearance 8. Written informed consent

Exclusion criteria

Exclusion criteria: 1. Any previous pelvic radiotherapy 2. Para-aortic nodal involvement above the level of the common iliac nodes or L3/L4 (if biopsy proven or >= 10 mm short axis diameter on CT) 3. FIGO STAGE IIIA 4. Patients assessed at presentation as requiring interstitial brachytherapy treatment 5. Patients with bilateral hydronephrosis unless at least one side has been stented and renal function fulfills the required inclusion criteria 6. Evidence of metastases 7. Diagnosis of Crohnâ??s disease or ulcerative colitis 8. Peripheral neuropathy > grade 2 (as per CTCAE) 9. Patients who have undergone a previous hysterectomy or will have a hysterectomy as part of their initial cervix cancer therapy 10. Patients with other invasive malignancies who had (or have) any evidence of the other cancer present within the last 5 years 11. Patients who are pregnant or lactating 12. Any contraindication to cisplatin 13. Serious uncontrolled medical condition 14. HIV positive

Design outcomes

Primary

MeasureTime frame
a. Categorize locally advanced cervical cancers into immune inflamed and immune suppressed based on immune cell infiltration b. Tumour micro-environment inflammatory cells immune profiling c. Evaluate response rates to standard chemoradiotherapy and progression free survival versus immune cell infiltration Timepoint: Eighteen months and 24 months

Secondary

MeasureTime frame
N/ATimepoint: N/A

Countries

India

Contacts

Public ContactPritee A Patil

NCI AIIMS New Delhi

drpritee184@gmail.com9870320544

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026